Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Canadian Lung Association Research Studentship

University of British Columbia

$10,666.00

The physiological mechanisms of improved exertional dyspnea and functional exercise capacity associated with antifibrotic therapy in patients with idiopathic pulmonary fibrosis (IPF)

FY 2022-23

Summary
This study is uniquely positioned to characterize the structure-function-symptom response and to determine how Nintedanib improves IPF outcomes. This will be the first study to correlate lung imaging measures with improvements in exercise capacity and breathlessness due to a pharmaceutical intervention in IPF. Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease of unknown cause, which leads to scarring of the lungs and results in debilitating reductions of both exercise tolerance and functional abilities. This is strongly associated with reduced quality of life and mortality. Improving breathlessness and reducing functional limitations are therefore critical goals in the management of IPF. Nintedanib, an oral drug, reduces scarring of the lungs and slows the progressive decline of respiratory health seen in IPF. However, few studies have assessed how this therapy affects important clinical outcomes, such as breathlessness and exercise tolerance. Moreover, the mechanisms by which this therapeutic intervention improves lung health remain relatively unknown. This study aims to delve deeper into the effects of nintedanib on breathlessness, cardiorespiratory measures (e.g., heart rate, breathing frequency, ventilation etc.,), and breathing mechanics. Further, it will assess the relationship between lung imaging measures and changes in breathlessness and exercise tolerance. Lung imaging, cycle exercise testing, assessment of breathing muscles (diaphragm and neck) activity, and breathlessness questionnaires will be used to find novel correlations between lung structure and function and Nintedanib use, as these changes may go undetected with routine lung function testing. The results of our study will further our understanding of the physiological mechanisms of exercise intolerance and breathlessness in IPF and add insight into the clinical benefits of Nintedanib in IPF. Moreover, it may provide insight into the characteristics or symptoms of IPF that see the greatest improvement with this anti-scarring therapy, which may allow for a better understanding of which individuals will yield the greatest benefit from this treatment option.
Program
Canadian Lung Association Research Studentship
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
476980
Name
Ferguson Olivia N
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Lung Association (Ottawa)
Prcname2
Special Cases
Projecttitle
The physiological mechanisms of improved exertional dyspnea and functional exercise capacity associated with antifibrotic therapy in patients with idiopathic pulmonary fibrosis (IPF)
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$10,666
Cihrequipment2
$0
Programname2
Canadian Lung Association Research Studentship
Keyworddelim
Dyspnea; Exercise; Idiopathic Pulmonary Fibrosis (Ipf); Magnetic Resonance Imaging (Mri); Rehabilitation
Abstract
This study is uniquely positioned to characterize the structure-function-symptom response and to determine how Nintedanib improves IPF outcomes. This will be the first study to correlate lung imaging measures with improvements in exercise capacity and breathlessness due to a pharmaceutical intervention in IPF. Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease of unknown cause, which leads to scarring of the lungs and results in debilitating reductions of both exercise tolerance and functional abilities. This is strongly associated with reduced quality of life and mortality. Improving breathlessness and reducing functional limitations are therefore critical goals in the management of IPF. Nintedanib, an oral drug, reduces scarring of the lungs and slows the progressive decline of respiratory health seen in IPF. However, few studies have assessed how this therapy affects important clinical outcomes, such as breathlessness and exercise tolerance. Moreover, the mechanisms by which this therapeutic intervention improves lung health remain relatively unknown. This study aims to delve deeper into the effects of nintedanib on breathlessness, cardiorespiratory measures (e.g., heart rate, breathing frequency, ventilation etc.,), and breathing mechanics. Further, it will assess the relationship between lung imaging measures and changes in breathlessness and exercise tolerance. Lung imaging, cycle exercise testing, assessment of breathing muscles (diaphragm and neck) activity, and breathlessness questionnaires will be used to find novel correlations between lung structure and function and Nintedanib use, as these changes may go undetected with routine lung function testing. The results of our study will further our understanding of the physiological mechanisms of exercise intolerance and breathlessness in IPF and add insight into the clinical benefits of Nintedanib in IPF. Moreover, it may provide insight into the characteristics or symptoms of IPF that see the greatest improvement with this anti-scarring therapy, which may allow for a better understanding of which individuals will yield the greatest benefit from this treatment option.
Competitiondate
202210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ferguson, Olivia N
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Circ &Respiratory Hlth~ $10,666~ $0~
University of British Columbia - $10,666 Grant (2022-… | Canada Spends